Literature DB >> 25250996

Impetigo: diagnosis and treatment.

Holly Hartman-Adams1, Christine Banvard1, Gregory Juckett1.   

Abstract

Impetigo is the most common bacterial skin infection in children two to five years of age. There are two principal types: nonbullous (70% of cases) and bullous (30% of cases). Nonbullous impetigo, or impetigo contagiosa, is caused by Staphylococcus aureus or Streptococcus pyogenes, and is characterized by honey-colored crusts on the face and extremities. Impetigo primarily affects the skin or secondarily infects insect bites, eczema, or herpetic lesions. Bullous impetigo, which is caused exclusively by S. aureus, results in large, flaccid bullae and is more likely to affect intertriginous areas. Both types usually resolve within two to three weeks without scarring, and complications are rare, with the most serious being poststreptococcal glomerulonephritis. Treatment includes topical antibiotics such as mupirocin, retapamulin, and fusidic acid. Oral antibiotic therapy can be used for impetigo with large bullae or when topical therapy is impractical. Amoxicillin/clavulanate, dicloxacillin, cephalexin, clindamycin, doxycycline, minocycline, trimethoprim/sulfamethoxazole, and macrolides are options, but penicillin is not. Natural therapies such as tea tree oil; olive, garlic, and coconut oils; and Manuka honey have been anecdotally successful, but lack sufficient evidence to recommend or dismiss them as treatment options. Treatments under development include minocycline foam and Ozenoxacin, a topical quinolone. Topical disinfectants are inferior to antibiotics and should not be used. Empiric treatment considerations have changed with the increasing prevalence of antibiotic-resistant bacteria, with methicillin-resistant S. aureus, macrolide-resistant streptococcus, and mupirocin-resistant streptococcus all documented. Fusidic acid, mupirocin, and retapamulin cover methicillin-susceptible S. aureus and streptococcal infections. Clindamycin proves helpful in suspected methicillin-resistant S. aureus infections. Trimethoprim/sulfamethoxazole covers methicillin-resistant S. aureus infection, but is inadequate for streptococcal infection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25250996

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  24 in total

Review 1.  Management of impetigo and cellulitis: Simple considerations for promoting appropriate antibiotic use in skin infections.

Authors:  Lynette Kosar; Tessa Laubscher
Journal:  Can Fam Physician       Date:  2017-08       Impact factor: 3.275

2. 

Authors:  Lynette Kosar; Tessa Laubscher
Journal:  Can Fam Physician       Date:  2017-08       Impact factor: 3.275

Review 3.  Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns.

Authors:  Deborah A Williamson; Glen P Carter; Benjamin P Howden
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

Review 4.  Bedside Diagnostics for Infections: A Guide for Dermatologists.

Authors:  Frank T Winsett; Shaunak G Patel; Brent C Kelly
Journal:  Am J Clin Dermatol       Date:  2020-10       Impact factor: 7.403

Review 5.  Desmosomes in acquired disease.

Authors:  Sara N Stahley; Andrew P Kowalczyk
Journal:  Cell Tissue Res       Date:  2015-03-21       Impact factor: 5.249

6.  Case Report and Literature Review of Impetigo-Like Tinea Faciei.

Authors:  Fangfang Zhang; Yahui Feng; Sisi Wang; Dongmei Li; Dongmei Shi
Journal:  Infect Drug Resist       Date:  2022-05-12       Impact factor: 4.177

7.  Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.

Authors:  Theodore Rosen; Nuria Albareda; Noah Rosenberg; Fernando García Alonso; Sandra Roth; Ilonka Zsolt; Adelaide A Hebert
Journal:  JAMA Dermatol       Date:  2018-07-01       Impact factor: 10.282

8.  Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents.

Authors:  Antonio Torrelo; Ramon Grimalt; Xavier Masramon; Núria Albareda López; Ilonka Zsolt
Journal:  Dermatology       Date:  2020-01-20       Impact factor: 5.366

Review 9.  Zosteriform impetigo: Wolf's isotopic response in a cutaneous immunocompromised district.

Authors:  Philip R Cohen
Journal:  Dermatol Pract Concept       Date:  2015-07-31

10.  Hospital admissions for skin infections among Western Australian children and adolescents from 1996 to 2012.

Authors:  Tasnim Abdalla; David Hendrickx; Parveen Fathima; Roz Walker; Christopher C Blyth; Jonathan R Carapetis; Asha C Bowen; Hannah C Moore
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.